COMMUNIQUÉS West-GlobeNewswire

Vivoryon Therapeutics N.V. to Report Q1 2024 Financial Results and Operational Progress on May 23, 2024
15/05/2024
Vivoryon Therapeutics N.V. to Report Q1 2024 Financial Results and Operational Progress on May 23, 2024 Halle (Saale) / Munich, Germany, May 15, 2024 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7 [...]
Pharming Group announces the early redemption of the remaining outstanding €125 million convertible bonds due 2025
15/05/2024
THIS NOTICE IS IMPORTANT AND REQUIRES THE IMMEDIATE ATTENTION OF BONDHOLDERS. IF BONDHOLDERS ARE IN ANY DOUBT AS TO THE ACTION THEY SHOULD TAKE, THEY SHOULD SEEK THEIR OWN FINANCIAL AND LEGAL ADVICE IMMEDIATELY FROM [...]
IHH Spearheads Cancer Care Leadership in Asia With Official Launch of Region’s First Private Proton Therapy Centre
15/05/2024
Mount Elizabeth Novena Hospital (MNH) Singapore is the first private hospital in the region to offer proton therapy; kicked off treatment for first patient on 10 May 2023. Centre has already treated more than 100 [...]
Eisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI® (lecanemab-irmb) for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer’s Disease Under the Fast Track Status
15/05/2024
TOKYO and CAMBRIDGE, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: [...]
UPDATE - SPR® Therapeutics Announces Publication of Study Providing Evidence of the Impact of SPRINT® PNS Treatment in Relieving Postoperative Knee Pain
15/05/2024
Pain Relief Resulted in Improved Objective Measure of Walking Ability at End of Treatment CLEVELAND, May 14, 2024 (GLOBE NEWSWIRE) -- SPR Therapeutics announced the publication of a multicenter double-blind randomized, [...]
ONWARD® Medical Schedules Webcast to Provide Q1 2024 Business Update
15/05/2024
EINDHOVEN, the Netherlands, May 15, 2024 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD), the medical technology company creating innovative spinal cord stimulation therapies to restore movement, function, and [...]
Aeterna Zentaris Reports First Quarter 2024 Financial Results
15/05/2024
Company ended the quarter with $29.5 million in cash DETECT-trial recruitment completed; Company continues to expect the completion of the trial in the second quarter and top-line data in the third quarter of 2024 All- [...]
FibroBiologics Files 2024 First Quarter Report
14/05/2024
HOUSTON, May 14, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 150+ patents issued and pending for the development of therapeutics and [...]
T2 Biosystems Announces CRG’s Conversion from Preferred Stock to Common Stock
14/05/2024
LEXINGTON, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) (the “Company”), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced that [...]
UNITY Biotechnology, Inc. Reports First Quarter 2024 Financial Results and Business Updates
14/05/2024
SOUTH SAN FRANCISCO, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today reported [...]
Lowell Farms Inc. Announces Unaudited First Quarter 2024 Financial and Operational Results
14/05/2024
SALINAS, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- Lowell Farms Inc. (the “Company”) (CSE: LOWL; OTCQX: LOWLF), a California cannabis company with advanced distribution and production capabilities including extraction, [...]
Psychemedics Corporation Reports First Quarter 2024 Financial Results
14/05/2024
DALLAS, May 14, 2024 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ: PMD), the world’s leading provider of hair testing for drugs of abuse, today announced financial results for the first quarter ended March 31, [...]
Natural Alternatives International, Inc. Announces Fiscal 2024 Q3 and YTD Results
14/05/2024
CARLSBAD, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- Natural Alternatives International, Inc. ("NAI") (Nasdaq: NAII), a leading formulator, manufacturer, and marketer of customized nutritional supplements, today announced [...]
Evoke Pharma Reports First Quarter 2024 Financial Results
14/05/2024
114% year-over-year increase in net product sales 70% prescriber growth in Q1 2024 compared to Q4 2023 Growing sales metrics reaffirms company’s $14M net revenue guidance for 2024 SOLANA BEACH, Calif., May 14, 2024 ( [...]
Autonomix Medical, Inc. (NASDAQ: AMIX) to Participate in the Virtual Investor Closing Bell Series
14/05/2024
Live webcast on Thursday, May 16 th at 4:00 PM ET THE WOODLANDS, TX, May 14, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing [...]
Vincerx Pharma Reports First Quarter 2024 Financial Results and Provides Corporate Update
14/05/2024
Vincerx continued to progress Phase 1 dose-escalation studies for VIP943, a potentially best-in-class anti-CD123 antibody-drug conjugate (ADC), and VIP236, a first-in-class small molecule-drug conjugate (SMDC) The [...]
Lumos Pharma Announces Positive End-of-Phase 2 Meeting with FDA and Reports First Quarter 2024 Financial Results
14/05/2024
Outcome from End-of-Phase 2 Meeting Supportive of a Placebo-Controlled Phase 3 Trial Updated 12 and 24-Month Data from Phase 2 OraGrowtH210 and OraGrowtH212 Trials Continue to Show Oral LUM-201 Achieves Significant [...]
NANOBIOTIX Announces US FDA Protocol Acceptance for New Randomized Phase 2 Study Evaluating NBTXR3 for Patients with Stage Three Lung Cancer
14/05/2024
PARIS and CAMBRIDGE, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘ Company ’’), a late-clinical stage biotechnology company pioneering nanoparticle-based therapeutic [...]
NANOBIOTIX annonce l'acceptation par l'Agence américaine du médicament, la FDA, d'un protocole pour une nouvelle étude randomisée de Phase 2 évaluant NBTXR3 pour les patients atteints d'un cancer du poumon de stade trois
14/05/2024
PARIS et CAMBRIDGE, Mass., 14 mai 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext : NANO –– NASDAQ : NBTX – la « Société »), société française de biotechnologie en phase de développement clinique avancé, pionnière des [...]

Pages